Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: Phase 2, Safety and Efficacy Study of Isatuximab, an Anti-CD38 Monoclonal Antibody, Administered by Intravenous (IV) Infusion in Patients With Relapsed or Refractory T-acute Lymphoblastic Leukemia (T-
Brief Summary:
Primary Objective:
To evaluate the efficacy of isatuximab.
Secondary Objectives: